Teladoc Health (TDOC) Issues Q1 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its first quarter earnings guidance on Wednesday. The company provided EPS guidance of (0.46)-(0.44) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.30). The company issued revenue guidance of $126-129 million, compared to the consensus revenue estimate of $131.13 million.Teladoc Health also updated its FY 2019 guidance to $-1.66–1.52 EPS.

Several analysts have recently weighed in on TDOC shares. Cantor Fitzgerald reaffirmed a hold rating and set a $83.00 price target on shares of Teladoc Health in a research note on Monday, January 7th. Zacks Investment Research raised shares of Teladoc Health from a sell rating to a hold rating in a research note on Tuesday, February 5th. TheStreet raised shares of Teladoc Health from a d+ rating to a c rating in a research note on Wednesday, February 20th. Berenberg Bank initiated coverage on shares of Teladoc Health in a research note on Thursday, January 31st. They issued a buy rating and a $80.00 price objective for the company. Finally, Chardan Capital lifted their price target on shares of Teladoc Health from $98.00 to $100.00 and gave the stock a buy rating in a report on Friday, November 2nd. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Teladoc Health has an average rating of Buy and an average price target of $83.16.

Get Teladoc Health alerts:

Shares of TDOC traded up $1.84 during trading hours on Friday, reaching $66.20. 35,128 shares of the company traded hands, compared to its average volume of 1,308,039. The firm has a market capitalization of $4.67 billion, a PE ratio of -40.07 and a beta of 1.47. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99. Teladoc Health has a 12-month low of $37.85 and a 12-month high of $89.05.

In other news, insider Lewis Levy sold 640 shares of the business’s stock in a transaction on Monday, December 17th. The shares were sold at an average price of $50.00, for a total transaction of $32,000.00. Following the sale, the insider now directly owns 640 shares of the company’s stock, valued at $32,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jason N. Gorevic sold 30,000 shares of the business’s stock in a transaction on Wednesday, December 19th. The shares were sold at an average price of $49.55, for a total transaction of $1,486,500.00. Following the sale, the chief executive officer now directly owns 536,184 shares in the company, valued at $26,567,917.20. The disclosure for this sale can be found here. Insiders have sold 130,745 shares of company stock worth $7,911,090 over the last three months. Corporate insiders own 3.95% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Teladoc Health (TDOC) Issues Q1 Earnings Guidance” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/4190463/teladoc-health-tdoc-issues-q1-earnings-guidance.html.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Trading Strategy Methods and Types